Business Context and Reporting Period
This Form 6-K filing reports on the Annual General Meeting of Shareholders held by BiondVax Pharmaceuticals Ltd. (now Scinai Immunotherapeutics Ltd.) on August 24, 2023. The filing details the voting results for eleven proposals regarding corporate governance, executive compensation, and a corporate name change.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a report of shareholder voting outcomes and does not contain financial statements or operational metrics.
Material Changes and Corporate Actions
- Corporate Name Change: Shareholders approved changing the company name to "Scinai Immunotherapeutics Ltd." or a similar name containing "Scinai," subject to regulatory approval.
- Board Composition: Shareholders approved the re-election of Professor Avner Rotman and Mr. Samuel Moed to the Board of Directors.
- Articles of Association: Amendments were approved to align external director requirements with the Israel Companies Law and to reflect the new corporate name.
- Auditor Appointment: Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) was ratified as the auditor for 2023.
Compensation and Governance Proposals
- Director Compensation: Amendments to annual cash compensation for independent directors were approved.
- Director Equity: Shareholders approved the cancellation of existing options for non-executive directors and the grant of replacement options, as well as a new grant of options.
- Executive Compensation: A grant of 78,125 restricted share units to CEO Amir Reichman for 2022 performance was approved. Additionally, a cash bonus for 2022 for Chairman Mark Germain was approved.
- Policy Updates: Amendments to the Compensation Policy for Executive Officers and Directors were approved.
Investor Verification Checklist
- Verify the official registration of the name change to "Scinai Immunotherapeutics Ltd." with the Israel Registrar of Companies.
- Review the specific terms of the new option grants and restricted share units to assess potential dilution.
- Confirm the updated compensation policy details for executive officers and directors.
- Check subsequent filings for the company's financial status, as this 6-K contains no financial data.